Major improvement in thyroid cancer survival of elderly patients in the Nordic countries.

IF 5.3 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

European Journal of Endocrinology Pub Date : 2024-03-02 DOI:10.1093/ejendo/lvae015

František Zitrický, Anni Koskinen, Vaclav Liska, Asta Försti, Akseli Hemminki, Kari Hemminki

{"title":"Major improvement in thyroid cancer survival of elderly patients in the Nordic countries.","authors":"František Zitrický, Anni Koskinen, Vaclav Liska, Asta Försti, Akseli Hemminki, Kari Hemminki","doi":"10.1093/ejendo/lvae015","DOIUrl":null,"url":null,"abstract":"Objectives: We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.Design: Population-based survival study.Methods: Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.Results: In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.Conclusions: Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae015","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: We describe age-specific survival in thyroid cancer (TC) from Denmark, Finland, Norway, and Sweden over a 50-year period.

Design: Population-based survival study.

Methods: Relative 5-year survival data were obtained from the NORDCAN database for the years 1972-2021.

Results: In the first period 1972-1976, 5-year survival in TC in Finland, Norway, and Sweden was 90% or higher, but a strong negative step-wise age gradient was observed, which was worse for men than women. Over time, survival increased, and in the final period, 2017-2021, survival for all women and Danish men up to age 69 years was about 90% or higher and, for men from the other countries, only marginally lower. Even for older women survival reached 80%, for older men somewhat less.

Conclusions: Age disadvantage in TC survival was for the most part corrected over the 50-year period, and the remaining task is to boost survival for the oldest patients.

查看原文本刊更多论文

北欧国家老年甲状腺癌患者的生存率大幅提高。

目标：描述丹麦、芬兰、挪威和瑞典 50 年间甲状腺癌患者的年龄特异性生存率：我们描述了丹麦、芬兰、挪威和瑞典50年间甲状腺癌（TC）患者的年龄特异性生存率：设计：基于人群的生存研究：方法：从NORDCAN数据库中获取1972-2021年的5年相对生存率数据：在 1972-76 年的第一阶段，芬兰、挪威和瑞典 TC 的 5 年存活率为 90% 或更高，但观察到强烈的负阶梯式年龄梯度，男性比女性更差。随着时间的推移，存活率不断提高，在 2017-21 年的最后一个阶段，69 岁以下的所有女性和丹麦男性的存活率约为 90% 或更高，其他国家男性的存活率仅略低于此。即使是老年女性的存活率也达到了80%，而老年男性的存活率则略低：结论：在 50 年的时间里，TC 存活率方面的年龄劣势在很大程度上得到了纠正，剩下的任务就是提高高龄患者的存活率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Endocrinology 医学-内分泌学与代谢

CiteScore

9.80

自引率

3.40%

发文量

354

审稿时长

1 months

期刊介绍： European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica. The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology. Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials. Equal consideration is given to all manuscripts in English from any country.